Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc ATYR with an Outperform rating and announced a ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma (NASDAQ:ATYR) shareholders have done very well over the last year, with the share ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...

aTyr Pharma, Inc. announced it will present three posters at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, showcasing its lead candidate efzofitimod ...